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A B S T R A C T
Two newer antithrombins have recently been tested for efficacy and safety in the treat-
ment of acute coronary syndromes (ACS), an indirect antithrombin, fondaparinux, 
a synthetic pentasacharide with anti-Xa properties, and a direct thrombin inhibitor, 
bivalirudin, having an anticoagulant effect against both free and clot-bound thrombin. 
Both these newer antithrombotic agents are recommended in current guidelines as 
anthithrombotic therapies in ACS patients with their main advantage being increased 
safety due to reduced bleeding events.
The net clinical benefit of any antithrombotic drug for the treatment of acute 
coronary syndromes (ACS) is described by its favorable effects on major outcomes 
(mortality, reinfarction, stroke) and its unfavorable effects on bleeding. Traditionally, 
with most antithrombotic therapies an increased hemorrhagic risk is accepted in order 
to achieve better efficacy. Recently, the importance of bleeding as an adverse outcome 
has received wide attention.
Major bleeding in ACS is not rare. In GRACE, the multinational registry of ACS, 
4% of patients with unstable angina, ST-elevation myocardial infarction (STEMI) 
or non-STEMI had a major hemorrhage.1 In-hospital mortality was 18.6% in those 
patients who experienced major bleeding versus only 5.1% in those without such an 
adverse event. What is more interesting is the fact that the appearance of a non-fatal 
major bleeding event in hospital increases the long-term risk of death and carries a 
similar prognostic significance to re-infarction. The odds ratio (OR) for 6-month 
mortality is 5.6 for a patient with re-infarction in hospital and 4.5 for a patient with 
major hemorrhage in hospital.1
The antithrombin drugs that are commonly used in the treatment of ACS are 
unfractionated heparin (UFH) and low molecular weight heparins (LMWH). Both 
are indirect thrombin inhibitors (requiring antithrombin-III) with anti-Xa and anti-II 
properties. Both have proved to be effective in reducing death or myocardial infarc-
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tion in randomized clinical trials with a small and acceptable 
increase in major bleedings. Consequently they both have a 
class I indication in current practice guidelines.2 Enoxaparin 
has gained popularity because of its practicality. A meta-analy-
sis of trials comparing enoxaparin with UFH showed similar 
mortality (3 vs 3%), marginally less re-infarction (10.1 vs 11%), 
with no increase in major bleeding; RR 1.04).3
Two newer antithrombins have recently been tested for 
efficacy and safety in the treatment of ACS. Fondaparinux 
is a synthetic pentasacharide with exclusive anti-Xa proper-
ties. It is an indirect antithrombin (like the LMWH) with 
excellent bioavailability, longer half-life (once daily subcu-
taneous administration), resistance to platelet factor 4 and 
no thrombocytopenia risk. The OASIS-5 trial randomized 
20,000 patients with ACS to enoxaparin 1 mg/Kg twice daily 
or fondaparinux 2.5 mg once daily.4 The composite end-point 
of death, infarction, refractory ischemia at day 9 was identical 
in the two treatment groups (hazard ratio-HR 1.01). However, 
major bleeding events were halved with fondaparinux (2.1% 
vs 4%; p<0.00001). At 6 months, mortality was significantly 
lower with fondaparinux (5.6% vs 6.3%; p=0.037). This 
reduction is mainly driven by the early avoidance of major 
bleeding events.
Direct thrombin inhibitors have an anticoagulant effect 
against both free and clot-bound thrombin, are resistant to 
plasma protein inactivation and achieve stable aPTT levels. 
Bivalirudin has been tested in patients with ACS treated with an 
early invasive strategy.5 The three treatment arms were UFH 
(or enoxaparin) + IIb/IIIa inhibitor, bivalirudin + IIb/IIIa 
inhibitor and bivalirudin alone. The composite end-point of 
death, myocardial infarction and urgent revascularization was 
7.3%, 7.7% and 7.8% respectively (p= ns). Major bleeding 
rates were 5.7%, 5.3% and 3% (p<0.001 for bivalirudin alone 
vs heparin +IIb/IIIa inhibitor). Similarly, less bleeding rates 
were noted in patients undergoing percutaneous coronary in-
tervention treated with bivalirudin in comparison with UFH+ 
IIb/IIIa inhibitors.6
Both fondaparinux and bivalirudin are recommended 
in current guidelines as anthithrombitic therapies in ACS 
patients with their main advantage being increased safety due 
to reduced bleeding events.2 Further studies will be needed in 
ACS patients to identify the optimal antithrombotic regimen 
which will suppress ischemic complications while at the same 
time reduce hemorrhagic complications.
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